Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment

• ClinicalTrials.gov Identifier: NCT02836873
• Recruitment Status: Completed
• First Posted: July 19, 2016
• Results First Posted: April 27, 2021
• Last Update Posted: June 30, 2021
• Sponsor: Theracos
• Information provided by (Responsible Party): Theracos

Tracking Information

• First Submitted Date: July 14, 2016
• First Posted Date: July 19, 2016
• Results First Submitted Date: March 30, 2021
• Results First Posted Date: April 27, 2021
• Last Update Posted Date: June 30, 2021
• Actual Study Start Date: September 23, 2016
• Actual Primary Completion Date: January 11, 2018 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: March 30, 2021)

Change From Baseline in HbA1c at 24 Weeks [ Time Frame: 24 weeks ]

The primary efficacy objective of this trial is to evaluate the placebo-adjusted change in HbA1c from baseline after 24 weeks of treatment with 20 mg bexagliflozin tablets in type 2 diabetic subjects with moderate renal impairment.

Original Primary Outcome Measures (submitted: July 14, 2016)

Change in HbA1c at 24 weeks [ Time Frame: 24 weeks ]

The primary efficacy objective of this trial is to evaluate the placebo-adjusted change in HbA1c from baseline after 24 weeks of treatment with 20 mg bexagliflozin tablets in type 2 diabetic subjects with moderate renal impairment.

Current Secondary Outcome Measures (submitted: March 30, 2021)

• Change in Body Weight From Baseline to Week 24 in Subjects With a BMI ≥ 25 kg/m2 [ Time Frame: 24 weeks ]
  A secondary objective is to evaluate the effect of bexagliflozin 20 mg on the placebo-adjusted change in BMI from baseline to week 24 in subjects with a BMI ≥ 25 kg/m2.
• Change From Baseline in Systolic Blood Pressure (SBP) in Subjects With Baseline SBP ≥ 130 mm Hg at Week 24 [ Time Frame: 24 weeks ]
  A secondary objective is to evaluate the effect of bexagliflozin 20 mg on the placebo-adjusted change from baseline in SBP to in subjects with baseline SBP ≥ 130 mm Hg at Week 24.
• Change From Baseline in HbA1c in Subjects With Stage 3a CKD (eGFR 45 to 59 mL/Min/1.73 m2) at Week 24 [ Time Frame: 24 weeks ]
  A secondary objective is to evaluate the effect of bexagliflozin 20 mg on the placebo-adjusted change in HbA1c from baseline in subjects with stage 3a CKD (eGFR 45 to 59 mL/min/1.73 m2) at week 24.
• Change From Baseline in HbA1c in Subjects With Stage 3b CKD (eGFR 30 to 44 mL/Min/1.73 m2) at Week 24 [ Time Frame: 24 weeks ]
  A secondary objective is to evaluate the effect of bexagliflozin 20 mg on the placebo-adjusted change in HbA1c from baseline in subjects with stage 3b CKD (eGFR 30 to 44 mL/min/1.73 m2) at week 24.

Original Secondary Outcome Measures (submitted: July 14, 2016)

• Change in body weight at 24 weeks in subjects with baseline body mass index (BMI) ≥ 25 kg/m [ Time Frame: 24 weeks ]
  A secondary objective is to evaluate the effect of 20 mg bexagliflozin on the placebo-adjusted change in BMI from baseline to week 24 in subjects with a BMI ≥ 25 kg/m2.
• Change in systolic blood pressure (SBP) at 24 weeks in subjects with baseline SBP ≥ 130 mmHg [ Time Frame: 24 weeks ]
  A secondary objective is to evaluate the effect of 20 mg bexagliflozin on the placebo-adjusted change in SBP from baseline to week 24 in subjects with baseline SBP ≥ 130 mmHg.
• Change in HbA1c at 24 weeks in subjects with eGFR 45 to 59 mL/min/1.73 m2 at week 24 [ Time Frame: 24 weeks ]
  A secondary objective is to evaluate the effect of 20 mg bexagliflozin on the placebo-adjusted change in HbA1c from baseline to week 24 in subjects with eGFR 45 to 59 mL/min/1.73 m2 at week 24.
• Change in HbA1c at 24 weeks in subjects with eGFR 30 to 44 mL/min/1.73 m2 at week 24 [ Time Frame: 24 weeks ]
  A secondary objective is to evaluate the effect of 20 mg bexagliflozin on the placebo-adjusted change in HbA1c from baseline to week 24 in subjects with eGFR 30 to 44 mL/min/1.73 m2 at week 24.

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
• Official Title: A Double Blind Placebo Controlled Study to Evaluate the Effect of Bexagliflozin Tablets on Hemoglobin A1c in Patients With Type 2 Diabetes Mellitus and Moderate Renal Impairment
• Brief Summary: This was a phase 3, multi-center, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of oral administration of bexagliflozin at 20 mg versus placebo in subjects with T2DM, moderate renal impairment and inadequate glycemic control.

Detailed Description

The phase 3, double-blind, placebo-controlled parallel-group study was conducted at investigative sites in the US, Japan, France and Spain. Approximately 300 subjects were to be randomly assigned to receive bexagliflozin tablets, 20 mg, or placebo in equal ratio for 24 weeks.

The study was to enrolled male and female participants who had T2DM with an HbA1c between 7.0 and 10.5% (inclusive) and stage 3 chronic kidney disease (CKD) as defined by an eGFR of ≥ 30 and< 60 mL min-1 per 1.73 m2 at the screening visit and one additional time of measurement between 1 and 12 months prior to screening. Subjects were either treatment naïve or were treated with a stable regimen of anti-diabetic medications.

All eligible subjects were to enter a one-week single-blind, placebo run-in period. Subjects who were compliant in taking run-in medication, had screening eGFR ≥ 30 and< 60 mL min-1 per 1.73 m2, and had stable GFR (no more than 20% change in eGFR between a historical value and the value determined at the screening visit) were eligible for randomization. Randomization was stratified by HbA1c level (7.0 to 8.5% or 8.6 to 10.5%), anti-diabetic treatment regimen and eGFR (30 - 44 mL min-1 per 1.73 m2 or 45 - 59 mL min-1 per 1.73 m2). At least 135 subjects in each of the eGFR groups were planned.

Study subjects were to schedule clinic visits at weeks 2, 6, 12, 18, and 24 for safety and efficacy evaluation. At weeks 2 and 18, the visits were to be conducted via phone interviews unless an in-person visit was considered clinically advisable. A final follow-up visit was to be conducted at week 26 or two weeks after the last dose of investigational product if the subject withdrew prior to week 24.

• Study Type: Interventional
• Study Phase: Phase 3
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Triple (Participant, Investigator, Outcomes Assessor); Primary Purpose: Treatment
• Condition: Type 2 Diabetes Mellitus

Intervention

• Drug: Bexagliflozin
  Bexagliflozin tablet, 20 mg
  Other Names:

  • EGT0001442
  • EGT0001474
• Drug: Placebo
  Placebo (inactive) tablet to match the active comparator

Study Arms

• Active Comparator: Bexagliflozin tablets, 20 mg
  Each subject will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study.
  Intervention: Drug: Bexagliflozin
• Placebo Comparator: Placebo tablets
  Each subject will receive a placebo (inactive) tablet once daily for the duration of the study.
  Intervention: Drug: Placebo

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: April 26, 2018): 312
• Original Estimated Enrollment (submitted: July 14, 2016): 300
• Actual Study Completion Date: January 11, 2018
• Actual Primary Completion Date: January 11, 2018 (Final data collection date for primary outcome measure)

Eligibility Criteria

Each subject was required to meet the following criteria at the time of enrollment to be eligible for the study:

1. To have been male or non-pregnant female ≥ 20 years of age. Women of childbearing potential were required to agree to use contraception throughout the study to avoid any possible pregnancy. Females who were surgically sterile (hysterectomy, oophorectomy) or postmenopausal (absence of menses for greater than 12 months and age > 45 years) were eligible if they tested negative on the urine pregnancy test.
2. To have had a diagnosis of T2DM with an HbA1c between 7.0 and 10.5% (inclusive) at the time of screening.
3. To have been treatment naïve or to have been treated with a stable regimen of anti-diabetic medications. At the time of screening, the doses and frequency of all anti-diabetic medications were to have been stable for 8 weeks.
4. To have had an eGFR ≥ 30 and < 60 mL min-1 per 1.73 m2 at 2 time points: screening (V1), and 1 additional time point between 1 and 12 months of screening (may be obtained from available medical records). The eGFR was calculated by the MDRD equation.
5. To have had a body mass index (BMI) ≤ 45 kg per m2 (inclusive).
6. To have been taking stable doses of medications for hypertension or hyperlipidemia (if applicable) for at least 30 days prior to randomization
7. To have had stable eGFR between the historic value and day of screening (no more than 20% change in eGFR between the most recent historical value and the value determined at the screening visit V1).

9.3.2 Exclusion Criteria

Potential participants who exhibited any of the following characteristics were excluded from the study:

1. A diagnosis of type 1 diabetes mellitus or maturity-onset diabetes of the young (MODY)
2. A hemoglobinopathy that could affect HbA1c measurement
3. Frequent symptomatic hypoglycemia (greater than one episode per week on average)
4. A history of genitourinary tract infection within 6 weeks of screening or history of ≥ 3 genitourinary infections requiring treatment within the last 6 months
5. A cancer, active or in remission for < 3 years (Non-melanoma skin cancer or basal cell carcinoma or carcinoma in situ of the cervix were not grounds for exclusion)
6. A history of alcohol or illicit drug abuse in the past 2 years
7. Evidence of abnormal liver function tests (total bilirubin or alkaline phosphatase > 1.5 × upper limit of normal (ULN) with the exception of isolated Gilbert's syndrome); or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 × ULN
8. A history of MI, stroke or hospitalization for heart failure, or hospitalization for unstable angina in the prior 3 months
9. Evidence of NYHA class IV heart failure at screening or randomization
10. A history of taking an SGLT2 inhibitor within 3 months of screening
11. Any condition, disease, disorder, or clinically relevant laboratory abnormality that, in the opinion of the PI, would jeopardize the subject's appropriate participation in this study or obscure the effects of treatment
12. A current status of pregnancy or breastfeeding
13. A current status of renal replacement therapy (peritoneal or hemodialysis) or a history of renal transplantation
14. A corrected serum calcium < 8 mg dL-1 at screening (V1) or randomization (V3)
15. Uncontrolled hypertension (systolic blood pressure >170 mm Hg or diastolic blood pressure >110 mm Hg)
16. Participation in another interventional trial or exposure to an investigational drug within 30 days or 7 half-lives of screening, whichever was longer
17. Previous exposure to bexagliflozin or EGT0001474
18. Evidence of having skipped dosing more than once during the run-in period
19. A fasting blood glucose value during the run-in period ≥ 250 mg dL-1 (13.9 mmol L-1) associated with severe clinical signs or symptoms of hyperglycemia
20. Any episode of symptomatic hypoglycemia during the run-in period in which symptoms were severe
21. An inability to comprehend or unwillingness to provide written informed consent in accordance with institutional and regulatory guidelines

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 20 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: France, Japan, Spain, United States

Administrative Information

• NCT Number: NCT02836873
• Other Study ID Numbers: THR-1442-C-448
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: Theracos
• Original Responsible Party: Same as current
• Current Study Sponsor: Theracos
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Study Director: Andrew Allegretti, M.D.; Massachusetts General Hospital

• PRS Account: Theracos
• Verification Date: June 2021